Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL2167550 | 0.95 | ALDH1A1 (0.55) | ALDH1A1LMNATSHRTDP1 | |
| Isopropyl Alcohol SCHEMBL7671116 | 0.95 | ALDH1A1 (0.67) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL5999087 | 0.95 | ALDH1A1 (0.67) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL27497569 | 0.95 | ALDH1A1 (0.67) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL52447 | 0.95 | — | — | |
| Isopropyl Alcohol SCHEMBL6554536 | 0.90 | — | — | |
| Isopropyl Alcohol SCHEMBL1150321 | 0.90 | — | — | |
| Isopropyl Alcohol SCHEMBL5858313 | 0.86 | ALDH1A1 (0.55) | ALDH1A1LMNATSHRTDP1 | |
| Methyl Alcohol SCHEMBL28014181 | 0.84 | — | — | |
| Chloroform SCHEMBL10009248 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200363419-A1 | A METHOD OF DIAGNOSING CANCER BASED ON LIPIDOMIC ANALYSIS OF A BODY FLUID | UNIVERZITA PARDUBICE (CZ) | 2020-11-19 | — | — | US | disclosed |
| US-20200281988-A1 | METHOD FOR TREATING CANCER | THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (US) | 2020-09-10 | — | — | US | disclosed |
| US-10751376-B1 | Method for treating cancer | ALI JASSIM M HASSAN M (KW) | 2020-08-25 | — | — | US | disclosed |
| US-10568915-B1 | Method of preparing a therapeutic composition using a preparation from epidermal gel secretions of catfish | ALI JASSIM M HASSAN M (KW) | 2020-02-25 | — | — | US | disclosed |
| US-10471105-B1 | Method for treating infertility | ALI JASSIM M HASSAN M (KW) | 2019-11-12 | — | — | US | disclosed |
| US-10406205-B1 | Method for curing diabetes and damaged organs and tissues affected by diabetes | ALI JASSIM M HASSAN M (KW) | 2019-09-10 | — | — | US | disclosed |
| US-20180267066-A1 | LIPODOMIC BIOMARKERS OF METABOLIC DISEASES IN DAIRY COWS | BRIGHAM YOUNG UNIVERSITY (US) | 2018-09-20 | — | — | US | disclosed |
| WO-2013173642-A1 | HIGH-THROUGHPUT LIPIDOMICS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130225694-A1 | COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2116524-B1 | The sodium salt of retinoyl-cysteic acid and retinoyl-cysteine sulfinic acid | ARDENIA INVESTMENTS LTD (GB) | 2012-10-03 | — | — | EP | disclosed |
| EP-1826198-A1 | Method for the synthesis of the sodium salt of retinoyl-cysteic acid and retinoyl-cysteine sulfinic acid | Ardenia Investments Ltd. (GB) | 2007-08-29 | — | — | EP | disclosed |
| EP-1387844-B1 | RETINOL DERIVATIVES POTENTIATION OF ACTIVE SUBSTANCES BY MICELLAR PREPARATION | ARDENIA INVESTMENTS LTD (GB) | 2007-06-13 | — | — | EP | disclosed |
| EP-1387844-A1 | RETINOL DERIVATIVES POTENTIATION OF ACTIVE SUBSTANCES BY MICELLAR PREPARATION | Ardenia Investments Ltd. (GB) | 2004-02-11 | — | — | EP | disclosed |
| US-6642271-B2 | Capable of potentiating the efficacy of therapeutically active compounds, for example cytotoxic compounds used in the treatment of cancer | ARDENIA INVESTMENTS, LTD. (GB) | 2003-11-04 | — | — | US | disclosed |
| US-20030050343-A1 | Novel potentiating compounds | OASMIA PHARMACEUTICAL AB (SE) | 2003-03-13 | — | — | US | disclosed |
| WO-2002092600-A1 | RETINOL DERIVATIVES POTENTIATION OF ACTIVE SUBSTANCES BY MICELLAR PREPARATION | ARDENIA INVESTMENTS LTD. (GB) | 2002-11-21 | — | — | WO | disclosed |
| US-4895853-A | Antitumor alkaloids | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0272056-A1 | New antitumor alkaloids | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1988-06-22 | — | — | EP | disclosed |
| US-4529561-A | Pressurized extrusion through a porous membrane | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1985-07-16 | — | — | US | disclosed |
| EP-0036676-B1 | METHOD OF MAKING UNIFORMLY SIZED LIPOSOMES AND LIPOSOMES SO MADE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225694-A1 | COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION | ALDH1A2, PDE6C, NQO1 | ALDH1A1 283/4885LMNA 780/4885TSHR 4475/4885 |
| US-20030050343-A1 | Novel potentiating compounds | MCL1, BAD, PMAIP1 | ALDH1A1 4014/4885LMNA 3296/4885TSHR 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.